China===Center for Drug Evaluation
Tracked across 1 events · 7 articles · First seen Mar 02, 2026 · Last active Mar 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
The China===Center for Drug Evaluation (CDE), a part of the China===National Medical Products Administration (NMPA), granted priority review to zurletrectinib and included it in the SPARK Program. These actions demonstrate the CDE's commitment to accelerating drug approval and encouraging pediatric anti-tumor drug development.
Mar 02, 2026 · 7 articles
China===National Medical Products Administration
part of
↔
China===Center for Drug Evaluation
The China===Center for Drug Evaluation is a key part of the China===National Med
NEWSDESK
Track China===Center for Drug Evaluation live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard